ArticleFrontiers in cell and developmental biology2026
TMEM39A acts as a novel profibrotic factor to activate hepatic stellate cells partially via the cell adhesion molecule signaling axis.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Hepatic stellate cell (HSC) transdifferentiation into myofibroblasts is a pivotal event in liver fibrosis, yet the underlying regulatory network remains elusive. This study explores the role of TMEM39A in HSC activation and its pro-fibrotic effects via the cell adhesion molecule (CAM) signaling axis. Methods: An Results: TMEM39A expression correlated positively with HSC activation. Overexpression of TMEM39A promoted LX-2 viability, migration, and upregulation of fibrotic markers (α-SMA, COL1A1) while suppressing apoptosis, whereas knockdown reversed these effects. Mechanistically, TMEM39A activated the CAM axis with specific ICAM-1 elevation. Alicaforsen treatment partially inhibited the activation of HSCs and the expression of fibrosis markers induced by TMEM39A. Conclusion: TMEM39A functions as a novel pro-fibrotic facilitator that promotes HSC activation at least partially through the CAM/ICAM-1 signaling axis. Our findings provide mechanistic insights into liver fibrosis and suggest TMEM39A and its downstream effectors as potential candidates for further therapeutic exploration, pending rigorous
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.